Three New Clinical Trials of Immunotherapy for Pancreatic Ductal Adenocarcinoma Beginning at Siteman Cancer Center

View Content

A $10.9 Million SPORE Grant for Pancreas Cancer expands on research funded by a prior pancreas cancer SPORE grant and various studies undertaken at Washington University. It targets novel therapeutic targets for the management of pancreatic ductal adenocarcinoma (PDAC), recognized as the most lethal variant of pancreatic cancer. Currently, the five-year survival rate for PDAC stands at less than 10%.